Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma regardless of biomarker status
The DUET phase 2a study met its primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps, reinforcing lunsekimig’s potential as a respiratory treatment
The exploratory VELVET phase 2b study did not meet its primary endpoint in moderate-to-severe atopic dermatitis
In all studies, lunsekimig was well tolerated
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.